Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM6B | O15054 | 2/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | AOC1 | P19801 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27147974 | 0.83 | KDM4C (0.43) | KDM4CKDM4EALDH1A1KDM6BKDM4D | |
| SCHEMBL18858140 | 0.81 | HDAC1 (0.43) | KDM4CKDM6BKDM4DHDAC3HDAC1 | |
| SCHEMBL4075291 | 0.78 | NAMPT (0.42) | HDAC1 | |
| SCHEMBL14357917 | 0.78 | HDAC1 (0.46) | KDM4CKDM4EALDH1A1GLAGAA | |
| SCHEMBL28994432 | 0.78 | TERT (0.48) | KDM4CKDM6BKDM4DHDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL5749683 | 0.77 | HDAC1 (0.45) | KDM4CKDM4EALDH1A1GLAGAA | |
| Hydrochloric Acid SCHEMBL29373586 | 0.77 | HDAC1 (0.45) | KDM4CKDM4EALDH1A1GLAGAA | |
| SCHEMBL9017891 | 0.76 | HDAC1 (0.49) | KDM4CKDM4EALDH1A1GLAGAA | |
| SCHEMBL15432248 | 0.76 | KDM4E (0.51) | KDM4CKDM4EALDH1A1GLAGAA | |
| SCHEMBL7653834 | 0.74 | HDAC1 (0.45) | KDM4CKDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | CA1 1397/4885CA2 458/4885KDM4C 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.